This Amendment No. 3 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on July 1, 2022, as amended on October 3, 2023 and February 7, 2024 (collectively, the “Original Schedule 13D” and, as amended and supplemented by this Amendment, this “Statement”), with respect to the Common Stock. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Original Schedule 13D is amended and supplemented by adding the following:
The Reporting Persons and their affiliates have not obtained any financing commitment or agreed to any financing terms regarding the transactions contemplated by the Draft Proposals (as defined below). Any third party financing for the transactions contemplated by the Draft Proposals remains subject to negotiation, and the Reporting Persons and their affiliates can provide no assurances that they will be able to negotiate definitive agreements or obtain financing on terms acceptable to them.
Item 4. Purpose of Transaction.
Item 4 of the Original Schedule 13D is amended and supplemented by adding the following:
On January 26, 2024, CoyCo 1, L.P. and CoyCo 2, L.P. (collectively, the “Investors”) submitted a request to the Issuer for a waiver of the standstill restrictions contained in the Investor Rights Agreement in order to permit one or more affiliates of the Investors to consider making a proposal to acquire all of the outstanding shares of the Issuer’s Common Stock not owned by the Investors and requested a response from the Issuer by no later than January 31, 2024 (the “January 26 Waiver Request”). The January 26 Waiver Request attached a form of proposal which included, among other things, a proposed purchase price of $13.75 per share in cash (the “January 26 Draft Proposal”).
The Issuer indicated to the Investors that it did not intend to take action on the January 26 Waiver Request, but asked that affiliates of the Investors engage in good faith discussions with representatives of TCP-ASC ACHI Series LLLP (“TCP-ASC”) regarding a potential transaction with the Issuer. As requested, representatives of affiliates of the Investors have been engaged in good faith discussions with representatives of TCP-ASC throughout the past several weeks, including multiple in-person meetings and discussions covering the following topics:
| • | | valuation and relative capital contribution; |
| • | | transaction sources and uses and pro forma capital structure; |
| • | | potential governance constructs, including specific approval rights, board configurations and other joint ownership provisions; and |
| • | | opportunities for the Issuer in a privately held setting. |
While there is not final agreement on terms as of this date, these discussions remain ongoing and there is active dialogue to enable alignment. The Investors believe that it is in the best interests of the Issuer, its customers and employees and the unaffiliated stockholders to accelerate a process whereby the board of directors of the Issuer, through a special committee, can do the work necessary to consider strategic alternatives, including the possibility of a transaction supported by New Mountain Capital, L.L.C. and the Investors (with or without participation by TCP-ASC). Therefore, on February 26, 2024, the Investors submitted a request to the Issuer for a waiver of the standstill restrictions contained in the Investor Rights Agreement, including (i) as the Investors may be deemed to have formed a group with TCP-ASC as a result of the discussions requested by the Issuer, a waiver of the restrictions on formation of a “group” (within the meaning of the Act and the rules of the Securities and Exchange Commission thereunder) with each of TCP-ASC (and/or its affiliates) and (ii) to make a proposal (with or without TCP-ASC) to acquire all of the outstanding shares of the Issuer’s Common Stock not owned by the Investors or any other group members (the “February 26 Waiver Request”). The February 26 Waiver Request attached a form of proposal which included, among other things, a proposed purchase price of $13.75 per share in cash and did not require the participation of any other existing stockholders (the “February 26 Draft Proposal” and, together with the January 26 Draft Proposal, the “Draft Proposals”).